NCT04257786 (ovarian cancer) is a NA clinical trial of 1ry cyto-reductive surgery in Advanced Cancer, sponsored by Assiut University.

Who is sponsoring NCT04257786?

NCT04257786 is sponsored by Assiut University.

What drugs are being tested in NCT04257786?

Interventions in NCT04257786: 1ry cyto-reductive surgery, Neoadjuvant chemotherapy followed by surgery.

What condition does NCT04257786 study?

NCT04257786 studies Advanced Cancer.

Is NCT04257786 still recruiting?

NCT04257786 is currently status unknown. Last updated 6 February 2020.

Last reviewed 2020-02-06 · How we verify

NCT04257786: ovarian cancer

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer

Status unknown NA Last updated 6 February 2020

What this trial tests

NA trial testing 1ry cyto-reductive surgery in Advanced Cancer in 80 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
30 December 2021

1 April 2022

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 March 2020
Primary completion	30 December 2021
Estimated completion	1 April 2022
Sites	1 location across Egypt

Drugs / interventions tested

1ry cyto-reductive surgery
Neoadjuvant chemotherapy followed by surgery

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Assiut University

Who can join

Adults 18 to 80, female only, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of efficacy of primary cyto-reductive surgery in patients with advanced primary epithelial ovarian cancer in Comparison to patients receiving neo-adjuvant chemotherapy (NAC) followed by surgery in complete excision of the tumor reaching R0 without significant morbidity.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL, Bryant A, Kehoe S, Morrison J. · · 2021 · cited 66× · PMID 34328210 · DOI 10.1002/14651858.cd005343.pub6
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.
Shawky M, Choudhary C, Coleridge SL, Bryant A, et al · · 2025 · cited 6× · PMID 39927569 · DOI 10.1002/14651858.cd005343.pub7
Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Patients with Advanced Primary Epithelial Ovarian Cancer in Low Resources Setting: A Randomized Clinical Trial.
Abutaleb H, Hussien A, Khalaf M, Badary DM, et al · · 2025 · PMID 40584804 · DOI 10.1007/s13224-024-02061-w

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04257786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 6 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04257786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing